NEW YORK, NY / ACCESSWIRE / June 28, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
PureCycle Technologies, Inc. (NASDAQ:PCT)
CONTACT JAKUBOWITZ ABOUT PCT:
https://claimyourloss.com/securities/purecycle-technologies-inc-loss-submission-form/?id=17201&from=1
Class Period : November 16, 2020 - May 5, 2021
Lead Plaintiff Deadline : July 12, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the technology PureCycle licensed from Procter & Gamble is not proven and presents serious issues even at lab scale; (ii) the challenges posed by the availability and competition for the raw materials necessary to commercialize the licensed technology are significant; (iii) PureCycle's financial projections are baseless; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Frequency Therapeutics, Inc. (NASDAQ:FREQ)
CONTACT JAKUBOWITZ ABOUT FREQ:
https://claimyourloss.com/securities/frequency-therapeutics-inc-loss-submission-form/?id=17201&from=1
Class Period : November 16, 2020 - March 22, 2021
Lead Plaintiff Deadline : August 2, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.
RLX Technology Inc. (NYSE:RLX)
CONTACT JAKUBOWITZ ABOUT RLX:
https://claimyourloss.com/securities/rlx-technology-inc-loss-submission-form/?id=17201&from=1
This lawsuit is on behalf of persons who purchased, or otherwise acquired, RLX American Depository Shares pursuant or traceable to the documents issued in connection with RLX's January 2021 initial public stock offering.
Lead Plaintiff Deadline : August 9, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: the Company's then-existing exposure to China's ongoing campaign to establish a national standard for e-cigarettes, which would bring them into line with ordinary cigarette regulations, and that RLX's reported financials were not nearly as robust as the offering materials projected, nor were they indicative of future results. As a result, investors purchased RLX shares at artificially inflated prices.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law
View source version on accesswire.com:
https://www.accesswire.com/653315/LAWSUITS-FILED-AGAINST-PCT-FREQ-and-RLX--JAKUBOWITZ-LAW-PURSUES-SHAREHOLDERS-CLAIMS
